Wasatch Advisors LP Grows Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

Wasatch Advisors LP grew its holdings in MacroGenics, Inc. (NASDAQ:MGNX - Free Report) by 37.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,488,493 shares of the biopharmaceutical company's stock after buying an additional 952,691 shares during the period. Wasatch Advisors LP owned 5.56% of MacroGenics worth $11,338,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. FMR LLC boosted its stake in MacroGenics by 1,230.1% during the third quarter. FMR LLC now owns 137,215 shares of the biopharmaceutical company's stock worth $451,000 after buying an additional 126,899 shares during the period. Stifel Financial Corp lifted its stake in MacroGenics by 19.7% during the third quarter. Stifel Financial Corp now owns 39,888 shares of the biopharmaceutical company's stock worth $131,000 after purchasing an additional 6,578 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of MacroGenics by 15.7% during the third quarter. Wellington Management Group LLP now owns 307,140 shares of the biopharmaceutical company's stock worth $1,010,000 after buying an additional 41,733 shares during the period. XTX Topco Ltd acquired a new stake in shares of MacroGenics in the third quarter valued at $37,000. Finally, Barclays PLC lifted its stake in MacroGenics by 97.1% during the 3rd quarter. Barclays PLC now owns 98,753 shares of the biopharmaceutical company's stock worth $325,000 after acquiring an additional 48,639 shares in the last quarter. 96.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. StockNews.com cut shares of MacroGenics from a "buy" rating to a "hold" rating in a research report on Friday, March 21st. HC Wainwright reduced their price target on MacroGenics from $4.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 25th. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $7.38.

MacroGenics Stock Performance

NASDAQ MGNX traded up $0.09 during trading on Monday, reaching $1.35. The company's stock had a trading volume of 562,614 shares, compared to its average volume of 1,134,758. MacroGenics, Inc. has a twelve month low of $0.99 and a twelve month high of $16.59. The firm has a market cap of $84.86 million, a price-to-earnings ratio of -0.85 and a beta of 2.23. The business's fifty day moving average price is $1.92 and its 200-day moving average price is $2.90.

MacroGenics (NASDAQ:MGNX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The firm had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million. As a group, sell-side analysts forecast that MacroGenics, Inc. will post -1.06 EPS for the current fiscal year.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.